DNDN) announced today that the underwriters of its previously announced public offering have exercised in full their option to purchase an additional 2,250,000 shares of common stock at the public offering price of $24.75 per share. The …
Providing that sometimes requires additional lengthy and expensive clinical trials. Although the near-term impact on Dendreon’s stock was severe — its shares plunged by 60 percent on the news — chances are good that Provenge or …
This suggests that analysts have very recently bumped up their estimates for DNDN, giving the stock a Zacks Earnings ESP of 38.89% heading into earnings season. Why is this Important? A positive reading for the Zacks Earnings ESP …
Angry investors let ‘er rip at Dendreon (DNDN) leadership at the Provenge-maker’s annual meeting on Wednesday. And with good reason: stock price decreased 82 percent over the last year. “The long-term future for Provenge is bright,” …
Dendreon's stock price took a hit, as investors tried to second-guess which way the winds were blowing at the agency. But as the previous panel had voted for approval with clinical data that fell short of statistical significance, it seemed unlikely …
Since 2011, Dendreon has changed chief executives twice and reduced its staff to about 700, about half the peak level. It still lost $22 million in the most recent quarter. The company’s stock was down about 70 percent, at about 30 cents a …
Despite Tuesday's sharp decline, Dendreon's shares have gained 0.89% in the last five trading sessions and 11.60% in …
Last year Valeant sold off equity interests in Dendreon Pharmaceuticals ... The company’s will continue to trade on the New York Stock Exchange and the Toronto Stock Exchange under its current ticker symbol VRX until July. Then the …
The stock is now higher by 1.18 at $29.32, with volume beginning to accelerate in the last few minutes. Dendreon Corp. is now challenging resistance at the highs of the year. The stock is trading at its highest level since mid-November.
Shares in Dendreon Corp have gone through the roof after the US firm presented highly positive late-stage data on its investigational prostate cancer vaccine Provenge. The company says that its Phase III IMPACT study of Provenge …